AbstractPsilocybin-assisted psychotherapy (PAP) has shown promise in treating mood and anxiety disorders in patients with cancer. However, patients with cancer often suffer from more than just depression and anxiety, and so far, PAP’s effect on other psychiatric symptoms remains largely unknown. To address this gap, we pooled previously unpublished data from two phase II, randomized, placebo-controlled crossover trials involving 79 participants with cancer-related distress and analyzed PAP’s effect on 9 psychiatric symptom dimensions: anxiety, depression, interpersonal sensitivity, hostility, obsession–compulsion, somatization, phobia, paranoia and psychosis.

摘要psilocybin辅助心理治疗（PAP）在治疗癌症患者的情绪和焦虑症方面显示出前景。然而，癌症患者通常不仅仅患有抑郁和焦虑，到目前为止，PAP对其他精神症状的影响仍然很大程度上未知。为了弥补这一差距，我们汇总了先前未发表的两项II期随机安慰剂对照交叉试验的数据，这些试验涉及79名与癌症相关的痛苦参与者，并分析了PAP对9个精神症状维度的影响：焦虑，抑郁，人际敏感，敌意，强迫症，躯体化，恐惧症，偏执症和精神病。

PAP significantly improved anxiety, depression, interpersonal sensitivity, hostility, obsession–compulsion and somatization without inducing any lasting phobia, paranoia or psychosis. Clinical improvements were consistent between trials. Together, our findings suggest that PAP has the potential to be a comprehensive mental health treatment for patients with cancer..

。临床改善在试验之间是一致的。总之，我们的研究结果表明，PAP有可能成为癌症患者的综合心理健康治疗方法。。

Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Subscribe to this journalReceive 12 digital issues and online access to articles73,83 € per yearonly 6,15 € per issueLearn moreBuy this articlePurchase on SpringerLinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout

订阅本期刊每年可收到12期数字期刊并在线访问文章73,83欧元每期仅6,15欧元了解更多在Springerlink上购买本文立即访问全文PDFBuy NOW价格可能需要缴纳结帐期间计算的地方税

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

Fig. 1: Pooled flow diagram of participants across both clinical trials.Fig. 2: Multidimensional effects of PAP.

图1：两项临床试验参与者的汇总流程图。图2:PAP的多维效应。

Data availability

数据可用性

The clinical trial participants of both studies used in this Analysis did not consent to the public sharing of their raw data. However, anonymized individual participant data can be made available provided the following conditions are met: (1) there is a data-sharing agreement and (2) an analysis plan in place.

本分析中使用的两项研究的临床试验参与者不同意公开分享他们的原始数据。但是，如果满足以下条件，可以提供匿名的个人参与者数据：（1）有数据共享协议，（2）有分析计划。

Upon data sharing, data can only be used for the specified purposes. Requests for data can be made by contacting the corresponding author..

数据共享后，数据只能用于指定目的。可以通过联系通讯作者来请求数据。。

Code availability

代码可用性

There was no custom code used in this Analysis.

此分析中没有使用自定义代码。

ReferencesDerogatis, L. R. et al. The prevalence of psychiatric disorders among cancer patients. JAMA 249, 751–757 (1983).Article

Referencesdegoris，L.R.等人。癌症患者中精神疾病的患病率。JAMA 249751-757（1983）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Zabora, J., BrintzenhofeSzoc, K., Curbow, B., Hooker, C. & Piantadosi, S. The prevalence of psychological distress by cancer site. Psychooncology 10, 19–28 (2001).Article

Zabora，J.，BrintzenhofeSzoc，K.，Curbow，B.，Hooker，C。＆Piantadosi，S。癌症部位心理困扰的患病率。心理肿瘤学10,19-28（2001）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Peters, L., Brederecke, J., Franzke, A., de Zwaan, M. & Zimmermann, T. Psychological distress in a sample of inpatients with mixed cancer—a cross-sectional study of routine clinical data. Front Psychol 11, 591771 (2020).Article

Peters，L.，Brederecke，J.，Franzke，A.，de Zwaan，M。＆Zimmermann，T。混合癌症住院患者样本中的心理困扰-常规临床数据的横断面研究。《前沿心理学》11591771（2020）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Mitchell, A. J. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 12, 160–174 (2011).Article

Mitchell，A.J.等人，《肿瘤学、血液学和姑息治疗环境中抑郁、焦虑和适应障碍的患病率：94项基于访谈的研究的荟萃分析》。柳叶刀Oncol。12160-174（2011）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Pitman, A., Suleman, S., Hyde, N. & Hodgkiss, A. Depression and anxiety in patients with cancer. Br. Med. J. 361, k1415 (2018).Article

Pitman，A.，Suleman，S.，Hyde，N。＆Hodgkiss，A。癌症患者的抑郁和焦虑。《医学杂志》361，k1415（2018）。文章

Google Scholar

谷歌学者

Andersen, B. L. et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J. Clin. Oncol. 32, 1605–1619 (2014).Article

Andersen，B.L.等人，《成人癌症患者焦虑和抑郁症状的筛查、评估和护理：美国临床肿瘤学会指南改编》。J、 临床。Oncol公司。321605-1619（2014）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Derogatis, L. R., Abeloff, M. D. & Melisaratos, N. Psychological coping mechanisms and survival time in metastatic breast cancer. JAMA 242, 1504–1508 (1979).Article

Degratis，L.R.，Abeloff，M.D。和Melisaratos，N。转移性乳腺癌的心理应对机制和生存时间。JAMA 2421504-1508（1979）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Grassi, L. et al. Hostility in cancer patients as an underexplored facet of distress. Psychooncology 30, 493–503 (2021).Article

Grassi，L.等人，《癌症患者的敌意是痛苦的一个未被充分探索的方面》。心理肿瘤学30493-503（2021）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Grassi, L., Caruso, R. & Nanni, M. G. Somatization and somatic symptom presentation in cancer: a neglected area. Int. Rev. Psychiatry 25, 41–51 (2013).Article

Grassi，L.，Caruso，R。＆Nanni，M.G。癌症中的躯体化和躯体症状表现：一个被忽视的领域。Int.Rev.精神病学25,41-51（2013）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Andersen, B. L. et al. Management of anxiety and depression in adult survivors of cancer: ASCO guideline update. J. Clin. Oncol. 41, 3426–3453 (2023).Article

Andersen，B.L.等人，《癌症成年幸存者的焦虑和抑郁管理：ASCO指南更新》。J、 临床。Oncol公司。413426-3453（2023）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Zhang, L. et al. Cognitive behavioral therapy for anxiety and depression in cancer survivors: a meta-analysis. Sci. Rep. 12, 21466 (2022).Article

Zhang，L.等。癌症幸存者焦虑和抑郁的认知行为疗法：荟萃分析。科学。代表121466（2022）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Taylor, S. E., Falke, R. L., Shoptaw, S. J. & Lichtman, R. R. Social support, support groups, and the cancer patient. J. Consult. Clin. Psychol. 54, 608–615 (1986).Article

Taylor，S.E.，Falke，R.L.，Shoptaw，S.J。＆Lichtman，R.R。社会支持，支持团体和癌症患者。J、 咨询。临床。心理学。54608-615（1986）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Cain, E. N., Kohorn, E. I., Quinlan, D. M., Latimer, K. & Schwartz, P. E. Psychosocial benefits of a cancer support group. Cancer 57, 183–189 (1986).Article

Cain，E.N.，Kohorn，E.I.，Quinlan，D.M.，Latimer，K。＆Schwartz，P.E。癌症支持小组的心理社会益处。癌症57183-189（1986）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Salsman, J. M. et al. Psychosocial interventions for cancer survivors: a meta-analysis of effects on positive affect. J. Cancer Surviv. 13, 943–955 (2019).Article

Salsman，J.M.等人，《癌症幸存者的心理社会干预：对积极情绪影响的荟萃分析》。J、 癌症存活。13943-955（2019）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Ostuzzi, G., Matcham, F., Dauchy, S., Barbui, C. & Hotopf, M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst. Rev. 4, CD011006 (2018).PubMed

Ostuzzi，G.，Matcham，F.，Dauchy，S.，Barbui，C。＆Hotopf，M。用于治疗癌症患者抑郁症的抗抑郁药。Cochrane数据库系统。第4版，CD011006（2018）。PubMed出版社

Google Scholar

谷歌学者

Miovic, M. & Block, S. Psychiatric disorders in advanced cancer. Cancer 110, 1665–1676 (2007).Article

Miovic，M。＆Block，S。晚期癌症中的精神疾病。癌症1101665-1676（2007）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Ng, C. G., Boks, M. P., Zainal, N. Z. & de Wit, N. J. The prevalence and pharmacotherapy of depression in cancer patients. J. Affect. Disord. 131, 1–7 (2011).Article

Ng，C.G.，Boks，M.P.，Zainal，N.Z。＆de Wit，N.J。癌症患者抑郁症的患病率和药物治疗。J、 影响。混乱。131,1-7（2011）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Azari, L. et al. The efficacy and safety of ketamine for depression in patients with cancer: a systematic review. Int. J. Clin. Health Psychol. 24, 100428 (2024).Article

Azari，L。等人。氯胺酮治疗癌症患者抑郁症的疗效和安全性：系统评价。国际J.临床。健康心理学。。文章

PubMed

PubMed

Google Scholar

谷歌学者

Culp, C., Kim, H. K. & Abdi, S. Ketamine use for cancer and chronic pain management. Front. Pharmacol. 11, 599721 (2020).Article

Culp，C.，Kim，H.K。和Abdi，S。氯胺酮用于癌症和慢性疼痛管理。正面。药理学。11599721（2020）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Falk, E. et al. A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study. BMC Palliative Care 19, 1 (2020).Article

S-氯胺酮对姑息治疗患者焦虑的快速积极影响：一项回顾性初步研究。BMC姑息治疗19,1（2020）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Ross, S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int. Rev. Psychiatry 30, 317–330 (2018).Article

Ross，S。经典迷幻剂治疗癌症相关精神痛苦的治疗用途。Int.Rev.Psychiatry 30317–330（2018）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Carhart-Harris, R. L. & Goodwin, G. M. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 42, 2105–2113 (2017).Article

Carhart-Harris，R.L。和Goodwin，G.M。迷幻药的治疗潜力：过去，现在和未来。神经精神药理学422105-2113（2017）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 30, 1165–1180 (2016).Article

Ross，S.等人，《裸盖菇素治疗危及生命的癌症患者焦虑和抑郁后症状的快速持续缓解：一项随机对照试验》。J、 。301165-1180（2016）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30, 1181–1197 (2016).Article

Griffiths，R。R。等人。裸盖菇素在危及生命的癌症患者中产生显着且持续的抑郁和焦虑降低：一项随机双盲试验。J、 。301181-1197（2016）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637–1648 (2022).Article

Goodwin，G.M。等人，单剂量裸盖菇素治疗难治性抑郁症。N、 英语。J、 医学3871637-1648（2022）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Raison, C. L. et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330, 843–853 (2023).Article

Raison，C.L.等人，《单剂量裸盖菇素治疗重度抑郁症：一项随机临床试验》。JAMA 330843–853（2023）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griffiths, R. R. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 28, 983–992 (2014).Article

Johnson，M.W.，Garcia-Romeu，A.，Cosimano，M.P。＆Griffiths，R.R。5-HT2AR激动剂psilocybin治疗烟草成瘾的初步研究。J、 。28983-992（2014）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Bogenschutz, M. P. et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 79, 953–962 (2022).Article

Bogenschutz，M.P.等人，《裸盖菇素辅助心理治疗与安慰剂治疗成年酒精使用障碍患者后重度饮酒天数的百分比：一项随机临床试验》。JAMA精神病学79953-962（2022）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Ehrmann, K., Allen, J. J. B. & Moreno, F. A. Psilocybin for the treatment of obsessive–compulsive disorders. Curr. Top. Behav. Neurosci. 56, 247–259 (2022).Article

Ehrmann，K.，Allen，J。J。B。和Moreno，F。A。Psilocybin用于治疗强迫症。货币。顶部。行为。神经科学。56247-259（2022）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Schneier, F. R. et al. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. J. Psychiatr. Res. 161, 364–370 (2023).Article

Schneier，F.R.等人。单剂量裸盖菇素治疗5-羟色胺再摄取抑制剂抵抗性身体畸形障碍的初步研究。J、 精神病医生。第161364-370号决议（2023年）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Ledwos, N., Rodas, J. D., Husain, M. I., Feusner, J. D. & Castle, D. J. Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder. J. Psychopharmacol. 37, 3–13 (2023).Article

Ledwos，N.，Rodas，J.D.，Husain，M.I.，Feusner，J.D。和Castle，D.J。迷幻剂对进食障碍和身体畸形障碍的治疗用途。J、 。37，3-13（2023）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Derogatis, L. R. & Melisaratos, N. The Brief Symptom Inventory: an introductory report. Psychol. Med. 13, 595–605 (1983).Article

Degratis，L.R。＆Melisaratos，N。简要症状清单：介绍性报告。心理学。医学杂志13595-605（1983）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Sarparast, A., Thomas, K., Malcolm, B. & Stauffer, C. S. Drug–drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 239, 1945–1976 (2022).Article

Sarparast，A.，Thomas，K.，Malcolm，B。＆Stauffer，C.S。精神病药物与MDMA或psilocybin之间的药物-药物相互作用：系统综述。精神药理学2391945-1976（2022）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Kwan, A. C., Olson, D. E., Preller, K. H. & Roth, B. L. The neural basis of psychedelic action. Nat. Neurosci. 25, 1407–1419 (2022).Article

Kwan，A.C.，Olson，D.E.，Preller，K.H。＆Roth，B.L。迷幻作用的神经基础。自然神经科学。251407-1419（2022）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Carhart-Harris, R. L. & Nutt, D. J. Serotonin and brain function: a tale of two receptors. J. Psychopharmacol. 31, 1091–1120 (2017).Article

Carhart-Harris，R.L。和Nutt，D.J。血清素和大脑功能：两种受体的故事。J、 。311091-1120（2017）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Vollenweider, F. X. & Preller, K. H. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat. Rev. Neurosci. 21, 611–624 (2020).Article

Vollenweider，F.X。和Preller，K.H。迷幻药：神经生物学和治疗精神疾病的潜力。。21611-624（2020）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Petridis, P. D. A psychedelic state arises from desynchronized brain activity. Nature 632, 32–33 (2024).Article

Petridis，P.D。迷幻状态是由大脑活动不同步引起的。自然632,32-33（2024）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Yeo, B. T. et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J. Neurophysiol. 106, 1125–1165 (2011).Article

Yeo，B.T.等人。通过内在功能连接性估计的人类大脑皮层组织。J、 神经生理学。1061125-1165（2011）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Siegel, J. S. et al. Psilocybin desynchronizes the human brain. Nature 632, 131–138 (2024).Article

Siegel，J.S。等人。裸盖菇素使人脑失去同步。自然632131-138（2024）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Smallwood, J. et al. The default mode network in cognition: a topographical perspective. Nat. Rev. Neurosci. 22, 503–513 (2021).Article

Smallwood，J.等人，《认知中的默认模式网络：地形视角》。。22503-513（2021）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Zhou, H. X. et al. Rumination and the default mode network: meta-analysis of brain imaging studies and implications for depression. NeuroImage 206, 116287 (2020).Article

Zhou，H.X.等。反刍和默认模式网络：脑成像研究的荟萃分析及其对抑郁症的影响。。文章

PubMed

PubMed

Google Scholar

谷歌学者

Madsen, M. K. et al. Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. Eur. Neuropsychopharmacol. 50, 121–132 (2021).Article

马德森，M.K。等人。裸盖菇素诱导的大脑网络完整性和分离的变化与血浆裸盖菇素水平和迷幻体验相关。欧洲神经精神药理学。50121-132（2021）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Daws, R. E. et al. Increased global integration in the brain after psilocybin therapy for depression. Nat. Med. 28, 844–851 (2022).Article

Daws，R.E.等人在裸盖菇素治疗抑郁症后增加了大脑的整体整合。《自然医学》28844-851（2022）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Vargas, M. V. et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 379, 700–706 (2023).Article

Vargas，M.V。等人。迷幻剂通过激活细胞内5-HT2A受体来促进神经可塑性。科学379700-706（2023）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Calder, A. E. & Hasler, G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology 48, 104–112 (2023).Article

Calder，A.E。＆Hasler，G。对迷幻药诱导的神经可塑性的理解。神经精神药理学48104-112（2023）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Agin-Liebes, G. I. et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J. Psychopharmacol. 34, 155–166 (2020).Article

Agin-Liebes，G.I.等人。裸盖菇素辅助心理治疗对危及生命的癌症患者的精神和生存困扰的长期随访。J、 。34155-166（2020）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Gukasyan, N. et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J. Psychopharmacol. 36, 151–158 (2022).Article

Gukasyan，N。等人。裸盖菇素辅助治疗重度抑郁症的疗效和安全性：前瞻性12个月随访。J、 。36151-158（2022）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Yaden, D. B. & Griffiths, R. R. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol. Transl. Sci. 4, 568–572 (2021).Article

Yaden，D.B。和Griffiths，R.R。迷幻剂的主观效果对于其持久的治疗效果是必要的。ACS药理学。翻译。科学。4568-572（2021）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Belser, A. B. et al. Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J. Humanist. Psychol. 57, 354–388 (2017).Article

Belser，A.B.等人，《裸盖菇素辅助心理治疗的患者体验：解释性现象学分析》。J、 。心理学。57354-388（2017）。文章

Google Scholar

谷歌学者

Swift, T. C. et al. Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J. Humanist. Psychol. 57, 488–519 (2017).Article

Swift，T.C.等人，《餐桌上的癌症：裸盖菇素辅助心理治疗治疗癌症相关痛苦的经验》。J、 。心理学。57488-519（2017）。文章

Google Scholar

谷歌学者

Butler, M., Jelen, L. & Rucker, J. Expectancy in placebo-controlled trials of psychedelics: if so, so what? Psychopharmacology 239, 3047–3055 (2022).Article

巴特勒（Butler，M.）、杰伦（Jelen，L.）和鲁克（Rucker，J.）在迷幻药安慰剂对照试验中的预期：如果是，那又怎么样？精神药理学2393047-3055（2022）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Vodermaier, A., Linden, W. & Siu, C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J. Natl Cancer Inst. 101, 1464–1488 (2009).Article

Vodermaier，A.，Linden，W。＆Siu，C。癌症患者情绪困扰的筛查：评估工具的系统评价。J、 国家癌症研究所1011464-1488（2009）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Pirl, W. F. et al. Recommendations for the implementation of distress screening programs in cancer centers: report from the American Psychosocial Oncology Society (APOS), Association of Oncology Social Work (AOSW), and Oncology Nursing Society (ONS) joint task force. Cancer 120, 2946–2954 (2014).Article .

。癌症1202946-2954（2014）。文章。

PubMed

PubMed

Google Scholar

谷歌学者

Holm, S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6, 65–70 (1979).

Holm，S。一个简单的顺序拒绝多重测试程序。斯堪的纳维亚。J、 Stat.6，65-70（1979）。

Google Scholar

谷歌学者

Download referencesAcknowledgementsThe parent trials included in this Analysis were supported by grants from the Heffter Research Institute (R.R.G. and S.R.), the RiverStyx Foundation (R.R.G. and S.R.), the Betsy Gordon Foundation (R.R.G.), the Fetzer Institute (R.R.G.) and the New York University–Health and Hospitals Corporation–Clinical and Translational Science Institute grant UL1 TR000038 from the National Center for Advancing Translational Sciences, National Institutes of Health (NIH) (S.R.).

下载参考文献致谢本分析中包括的父母试验得到了海夫特研究所（R.R.G.和S.R.）、里弗斯特克斯基金会（R.R.G.和S.R.）、贝西·戈登基金会（R.R.G.）、费泽研究所（R.R.G.）和纽约大学-健康与医院公司-临床与转化科学研究所（National Center for Advanced Translation Sciences，National Institutes of Health）（S.R.）的资助UL1 TR000038。

Additional funding for the parent trials was provided by Carey and Claudia Turnbull (S.R.), W. Linton (R.R.G. and S.R.), R. Barnhart (S.R.), A. Altschul (S.R.), K. Fitzsimmons (S.R.), the McCormick Family (R.R.G.), G. Goldsmith (R.R.G. and S.R) and E. Malievskaia (R.R.G. and S.R.). Funding for the pooled analysis was provided by the Usona Institute scholarship (P.D.P), the NIH T32DA007250 (G.A.-L.) and the Canadian Institutes of Health Research (grant number 202110MFE-472921-HTB-272687) (R.J.Z.).

Carey和Claudia Turnbull（S.R.）、W.Linton（R.R.G.和S.R.）、R.Barnhart（S.R.）、A.Altschul（S.R.）、K.Fitzsimmons（S.R.）、McCormick家族（R.R.G.）、G.Goldsmith（R.R.G.和S.R.）和E.Malievskaia（R.R.G.和S.R.）为父母试验提供了额外资金。Usona研究所奖学金（P.D.P），NIH T32DA007250（G.A.-L.）和加拿大卫生研究院（批准号202110MFE-472921-HTB-272687）（R.J.Z.）提供了汇总分析的资金。

Sponsors did not have roles in the management, analysis or interpretation of the data, nor in the preparation or approval of the manuscript.Author informationAuthor notesDeceased: Roland R. Griffiths.Authors and AffiliationsNYU Langone Center for Psychedelic Medicine, Department of Psychiatry, New York University Grossman School of Medicine, New York, NY, USAPetros D.

赞助商在数据的管理，分析或解释以及手稿的准备或批准方面都没有任何作用。。作者和所属单位纽约大学格罗斯曼医学院精神病学系Yu Langone迷幻医学中心，纽约州纽约市，美国佩特罗斯D。

Petridis, Richard J. Zeifman, Michael P. Bogenschutz & Stephen RossDepartment of Psychiatry, Columbia University, New York, NY, USAJack GrinbandDepartment of Radiology, Columbia University, New York, NY, USAJack GrinbandDepartment of Psychiatry and Behavioral Science, UCSF, San Francisco, CA, USAGabrielle Agin-LiebesDepartment of Psychiatry, Yale University, New Haven, CT, USAGabrielle Agin-LiebesDepartme.

Petridis，Richard J.Zeifman，Michael P.Bogenschutz＆Stephen Ross纽约哥伦比亚大学精神病学系，USAJack Grinband纽约哥伦比亚大学放射学系，USAJack Grinband加州旧金山加州大学旧金山分校精神病学与行为科学系，USAgbrielle Agin LiebesDepartment of Psychiatry，耶鲁大学，纽黑文，康涅狄格州，USAgbrielle Agin LiebesDepartment me。

PubMed Google ScholarJack GrinbandView author publicationsYou can also search for this author in

PubMed Google ScholarJack GrinbandView作者出版物您也可以在

PubMed Google ScholarGabrielle Agin-LiebesView author publicationsYou can also search for this author in

PubMed Google ScholarConnor J. KinslowView author publicationsYou can also search for this author in

PubMed Google ScholarConnor J.KinslowView作者出版物您也可以在

PubMed Google ScholarRichard J. ZeifmanView author publicationsYou can also search for this author in

PubMed Google ScholarRichard J.ZeifmanView作者出版物您也可以在

PubMed Google ScholarMichael P. BogenschutzView author publicationsYou can also search for this author in

PubMed Google Scholarmamichael P.BogenschutzView作者出版物您也可以在

PubMed Google ScholarRoland R. GriffithsView author publicationsYou can also search for this author in

PubMed Google ScholarRoland R.GriffithsView作者出版物您也可以在

PubMed Google ScholarStephen RossView author publicationsYou can also search for this author in

PubMed Google ScholarStephen RossView作者出版物您也可以在

PubMed Google ScholarContributionsP.D.P. and S.R. conceived of the analysis. R.R.G. and S.R. provided deidentified individual participant data from their respective parent clinical trials. P.D.P. analyzed the data with support from J.G. and M.P.B. P.D.P., J.G., G.A.-L., C.J.K., R.J.Z., M.P.B., R.R.G.

PubMed谷歌学术贡献SP。D、 P.和S.R.构思了该分析。R、 R.G.和S.R.从各自的父母临床试验中提供了身份不明的个体参与者数据。P、 D.P.在J.G.和M.P.B.P.D.P.，J.G.，G.A.-L.，C.J.K.，R.J.Z.，M.P.B.，R.R.G.的支持下分析了数据。

and S.R. interpreted the results of the analysis. P.D.P. wrote the paper. P.D.P., J.G., G.A.-L., C.J.K., R.J.Z, M.P.B., R.R.G. and S.R. critically revised the article.Corresponding authorCorrespondence to.

和S.R.解释了分析结果。P、 民主党写了这篇论文。P、 D.P.，J.G.，G.A.-L.，C.J.K.，R.J.Z，M.P.B.，R.R.G.和S.R.批判性地修改了这篇文章。对应作者对应。

Petros D. Petridis.Ethics declarations

彼得罗斯·佩特里迪斯。道德宣言

Competing interests

相互竞争的利益

R.J.Z. is a post-doctoral fellow in the NYU Langone Psychedelic Medicine Research Training program funded by MindMed. M.P.B. is principal investigator of the NYU Langone Center for Psychedelic Medicine Research Training Program, funded by MindMed. M.P.B. has received research funding from Tilray Canada, the Multidisciplinary Association for Psychedelic Studies (MAPS) PBC, B.More Inc., the Heffter Research Institute, the Turnbull Family Foundation, the Fournier Family Foundation, Dr.

R、 J.Z.是由MindMed资助的纽约大学Langone迷幻医学研究培训计划的博士后研究员。M、 P.B.是由MindMed资助的纽约大学朗根迷幻药物研究中心培训计划的首席研究员。M、 P.B.获得了加拿大蒂尔雷（Tilray Canada）、多学科迷幻药研究协会（MAPS）PBC、B.More Inc.、赫夫特研究所、特恩布尔家族基金会、福尼尔家族基金会（Fournier Family Foundation）博士的研究资助。

Bronner’s Family Foundation, Bill Linton and the Riverstyx Foundation. M.P.B. serves on the Advisory Board of Ajna Labs LLC, Journey Colab and Bright Minds Biosciences, Inc. He is named as inventor on patent applications relating to the use of psilocybin for alcohol use disorder but has waived all rights and has no prospect of financial benefit.

布朗纳家族基金会、比尔·林顿和里弗斯特克斯基金会。M、 P.B.是Ajna Labs LLC、Travely Colab和Bright Minds Biosciences，Inc.的顾问委员会成员。他被提名为与使用裸盖菇素治疗酒精使用障碍有关的专利申请的发明人，但放弃了所有权利，也没有经济利益的前景。

S.R. is the Director of NYU Langone Center for Psychedelic Medicine Research Training Program, which is funded by MindMed. S.R. currently receives, or has received in the past 36 months, grant support for clinical research from the National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), Heffter Research Institute, Usona Institute, Council on Spiritual Practices (CSP), Multidisciplinary Association of Psychedelic Studies (MAPS) and Reset Pharmaceuticals.

S、 R.是纽约大学朗根迷幻医学研究中心培训项目的主任，该项目由MindMed资助。S、 R.目前或在过去36个月内获得了国家药物滥用研究所（NIDA），国家癌症研究所（NCI），赫夫特研究所，乌索纳研究所，精神实践委员会（CSP）的临床研究资助，迷幻药研究多学科协会（MAPS）和Reset Pharmaceuticals。

S.R. is listed as a coinventor in two provisional patent applications (N420838US and N419987US) related to the use of psilocybin to treat psychiatric and existential distress in cancer. These provisional patent applications were filed by New York University Grossman School of Medicine and licensed by Reset Pharmaceuticals.

S、 R.在两项临时专利申请（N420838US和N419987US）中被列为共同发明人，这两项临时专利申请涉及使用裸盖菇素治疗癌症中的精神病和生存困扰。这些临时专利申请由纽约大学格罗斯曼医学院提交，并由Reset Pharmaceuticals许可。

S.R. has waived all rights in relation to these provisional patent applications and has no prospect of financial gain related to any future commercialization effor.

S、 R.放弃了与这些临时专利申请有关的所有权利，并且没有任何未来商业化效果相关的财务收益前景。

Peer review

同行评审

Peer review information

同行评审信息

Nature Mental Health thanks Matthias Emanuel Liechti, Joshua Rosenblat and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

《自然心理健康》感谢马蒂亚斯·伊曼纽尔·利奇蒂、约书亚·罗森布拉特和另一位匿名审稿人为这项工作的同行评审做出的贡献。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Supplementary informationSupplementary InformationSupplementary Table 1 and Figs. 1 and 2.Reporting SummaryRights and permissionsSpringer Nature or its licensor (e.g.

Additional informationPublisher的注释Springer Nature在已发布的地图和机构隶属关系中的管辖权主张方面保持中立。补充信息补充信息补充表1和图1和图2。报告摘要权利和许可原告性质或其许可人（例如。

a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.Reprints and permissionsAbout this articleCite this articlePetridis, P.D., Grinband, J., Agin-Liebes, G.

协会或其他合作伙伴）根据与作者或其他权利持有人的出版协议对本文拥有专有权；本文接受稿件版本的作者自行存档仅受此类出版协议和适用法律的条款管辖。转载和许可本文引用本文Petridis，P.D.，Grinband，J.，Agin Liebes，G。

et al. Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer..

等。裸盖菇素辅助心理治疗可改善癌症患者多方面的精神症状。。

Nat. Mental Health (2024). https://doi.org/10.1038/s44220-024-00331-0Download citationReceived: 18 March 2024Accepted: 17 September 2024Published: 07 October 2024DOI: https://doi.org/10.1038/s44220-024-00331-0Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

《自然心理健康》（2024）。https://doi.org/10.1038/s44220-024-00331-0Download引文收到日期：2024年3月18日接受日期：2024年9月17日发布日期：2024年10月7日OI：https://doi.org/10.1038/s44220-024-00331-0Share。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供